Sorry, your browser does not support JavaScript!
Find a Treatment Center
Investor Relations
Contact Us
About Us
Our Mission
Our Story
Therapeutic Areas
Leadership
Kite Locations
Cell Therapy
Our Cell Therapy Technology
Our Therapies
Pipeline
Trials & Expanded Access
Clinical Trial Diversity
External Research Program (ERP)
Patient Resources
Patient Stories
Our Authorized Treatment Centers
Kite Konnect
Newsroom
Newsroom
Press Releases
Company Statements
Media Kit
Careers
Careers
Veteran Careers
Early Talent Programs
Culture & Benefits
Utility
Investor Relations
Contact Us
Kite Konnect®
Contact Us
Find a Treatment Center
Investor Relations
Newsroom
Recent Press Releases
January 30, 2024
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
December 21, 2023
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
Recent Company Statements
October 2, 2023
Kite Appoints Priti Hegde as Global Head of Research
Explore More
Media Inquiries
Gilead Newsroom
Twitter Feed